Libtayo gets a double with EU approvals in skin, lung cancerSanofi and Regeneron’s checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for Share XLibtayo gets a double with EU approvals in skin, lung cancerhttps://pharmaphorum.com/news/libtayo-gets-a-double-with-eu-approvals-in-skin-lung-cancer/
Sanofi/Regeneron’s Libtayo set for new skin cancer useSanofi and Regeneron plan to file their cancer immunotherapy Libtayo (cemiplimab) in a new indication following supportive findings Share XSanofi/Regeneron’s Libtayo set for new skin cancer usehttps://pharmaphorum.com/news/sanofi-regenerons-libtayo-set-for-new-skin-cancer-use/
